{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:56:50Z","timestamp":1786222610882,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870622"],"award-info":[{"award-number":["81870622"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Changsha Municipal Natural Science Foundation","award":["kq2014251"],"award-info":[{"award-number":["kq2014251"]}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["512191022"],"award-info":[{"award-number":["512191022"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Degree& Postgraduate Education Reform Project of Central South University","award":["512190112"],"award-info":[{"award-number":["512190112"]}]},{"name":"Scientific Research Project of Hunan Provincial Health Commission","award":["202112070631"],"award-info":[{"award-number":["202112070631"]}]},{"DOI":"10.13039\/501100010083","name":"Hunan Provincial Innovation Foundation for Postgraduate","doi-asserted-by":"publisher","award":["CX20210372"],"award-info":[{"award-number":["CX20210372"]}],"id":[{"id":"10.13039\/501100010083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-022-01910-7","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T12:05:46Z","timestamp":1661947546000},"page":"367-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk"],"prefix":"10.1007","volume":"46","author":[{"given":"C.","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-X.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.-Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-F.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.-L.","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-3024","authenticated-orcid":false,"given":"Z.-F.","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.-B.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.-M.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"1910_CR1","first-page":"1","volume":"843","author":"WHO Study Group","year":"1994","unstructured":"WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis report of a WHO study group. World Health Organ Tech Rep Ser 843:1\u2013129","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"6","key":"1910_CR2","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00198-017-3996-1","volume":"28","author":"AC Looker","year":"2017","unstructured":"Looker AC, Sarafrazi Isfahani N, Fan B, Shepherd JA (2017) Trends in osteoporosis and low bone mass in older US adults, 2005\u20132006 through 2013\u20132014. Osteoporos Int 28(6):1979\u20131988. https:\/\/doi.org\/10.1007\/s00198-017-3996-1","journal-title":"Osteoporos Int"},{"issue":"3","key":"1910_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 22(3):465\u2013475. https:\/\/doi.org\/10.1359\/jbmr.061113","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"1910_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/gl-2020-0524suppl","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A et al (2020) American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26(Suppl 1):1\u201346. https:\/\/doi.org\/10.4158\/gl-2020-0524suppl","journal-title":"Endocr Pract"},{"issue":"20","key":"1910_CR5","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Mar\u00edn F, Donley DW, Taylor KA et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028\u20132039. https:\/\/doi.org\/10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"issue":"15","key":"1910_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"1","key":"1910_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/ard.2008.092775","volume":"68","author":"TA van Geel","year":"2009","unstructured":"van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68(1):99\u2013102. https:\/\/doi.org\/10.1136\/ard.2008.092775","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1910_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E et al (2017) Imminent risk of fracture after fracture. Osteoporos Int 28(3):775\u2013780. https:\/\/doi.org\/10.1007\/s00198-016-3868-0","journal-title":"Osteoporos Int"},{"issue":"1","key":"1910_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11657-019-0598-x","volume":"14","author":"JD Adachi","year":"2019","unstructured":"Adachi JD, Berger C, Barron R, Weycker D, Anastassiades TP, Davison KS et al (2019) Predictors of imminent non-vertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian multicentre osteoporosis study (CaMos). Arch Osteoporos 14(1):53. https:\/\/doi.org\/10.1007\/s11657-019-0598-x","journal-title":"Arch Osteoporos"},{"issue":"1","key":"1910_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11657-020-00784-7","volume":"15","author":"AA Yusuf","year":"2020","unstructured":"Yusuf AA, Hu Y, Chandler D, Crittenden DB, Barron RL (2020) Predictors of imminent risk of fracture in medicare-enrolled men and women. Arch Osteoporos 15(1):120. https:\/\/doi.org\/10.1007\/s11657-020-00784-7","journal-title":"Arch Osteoporos"},{"issue":"4","key":"1910_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989x9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13(4):322\u2013338. https:\/\/doi.org\/10.1177\/0272989x9301300409","journal-title":"Med Decis Making"},{"issue":"4","key":"1910_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4):397\u2013409. https:\/\/doi.org\/10.2165\/00019053-199813040-00003","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1910_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D et al (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health 16(2):e1-5. https:\/\/doi.org\/10.1016\/j.jval.2013.02.010","journal-title":"Value Health"},{"issue":"1","key":"1910_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT et al (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO) and the US branch of the international osteoporosis foundation. Osteoporos Int 30(1):45\u201357. https:\/\/doi.org\/10.1007\/s00198-018-4744-x","journal-title":"Osteoporos Int"},{"issue":"10","key":"1910_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M et al (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316(10):1093\u20131103. https:\/\/doi.org\/10.1001\/jama.2016.12195","journal-title":"JAMA"},{"issue":"3","key":"1910_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson B, Str\u00f6m O, Eisman JA, Papaioannou A, Siris ES, Tosteson A et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967\u2013982. https:\/\/doi.org\/10.1007\/s00198-010-1424-x","journal-title":"Osteoporos Int"},{"issue":"7","key":"1910_CR17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00198-020-05765-7","volume":"32","author":"E S\u00f6reskog","year":"2021","unstructured":"S\u00f6reskog E, Borgstr\u00f6m F, Lindberg I, Str\u00f6m O, Willems D, Libanati C et al (2021) A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis. Osteoporos Int 32(7):1301\u20131311. https:\/\/doi.org\/10.1007\/s00198-020-05765-7","journal-title":"Osteoporos Int"},{"issue":"1","key":"1910_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00198-009-1032-9","volume":"21","author":"B Ettinger","year":"2010","unstructured":"Ettinger B, Black DM, Dawson-Hughes B, Pressman AR, Melton LJ 3rd (2010) Updated fracture incidence rates for the US version of FRAX. Osteoporos Int 21(1):25\u201333. https:\/\/doi.org\/10.1007\/s00198-009-1032-9","journal-title":"Osteoporos Int"},{"issue":"2","key":"1910_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00198-016-3772-7","volume":"28","author":"T Mori","year":"2017","unstructured":"Mori T, Crandall CJ, Ganz DA (2017) Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. Osteoporos Int 28(2):585\u2013595. https:\/\/doi.org\/10.1007\/s00198-016-3772-7","journal-title":"Osteoporos Int"},{"key":"1910_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115286","volume":"134","author":"E S\u00f6reskog","year":"2020","unstructured":"S\u00f6reskog E, Str\u00f6m O, Sp\u00e5ng\u00e9us A, \u00c5kesson KE, Borgstr\u00f6m F, Banefelt J et al (2020) Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone 134:115286. https:\/\/doi.org\/10.1016\/j.bone.2020.115286","journal-title":"Bone"},{"issue":"12","key":"1910_CR21","first-page":"1","volume":"69","author":"E Arias","year":"2020","unstructured":"Arias E, Xu J (2020) United States life tables, 2018. Natl Vital Stat Rep 69(12):1\u201345","journal-title":"Natl Vital Stat Rep"},{"issue":"6","key":"1910_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens P, Magaziner J, Col\u00f3n-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B et al (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152(6):380\u2013390. https:\/\/doi.org\/10.7326\/0003-4819-152-6-201003160-00008","journal-title":"Ann Intern Med"},{"issue":"5","key":"1910_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/s8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32(5):468\u2013473. https:\/\/doi.org\/10.1016\/s8756-3282(03)00061-9","journal-title":"Bone"},{"issue":"6","key":"1910_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0033-3506(05)80614-6","volume":"105","author":"MJ Parker","year":"1991","unstructured":"Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105(6):443\u2013446","journal-title":"Public Health"},{"issue":"1","key":"1910_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Od\u00e9n A, Sernbo I, Redlund-Johnell I, Petterson C et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38\u201342. https:\/\/doi.org\/10.1007\/s00198-003-1490-4","journal-title":"Osteoporos Int"},{"issue":"2","key":"1910_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","volume":"49","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2019) Cost-effectiveness of sequential treatment with abaloparatide vs teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum 49(2):184\u2013196. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.01.006","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1910_CR27","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104(5):1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2019-00192","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1910_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","volume":"24","author":"N Freemantle","year":"2013","unstructured":"Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S et al (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24(1):209\u2013217. https:\/\/doi.org\/10.1007\/s00198-012-2068-9","journal-title":"Osteoporos Int"},{"issue":"11","key":"1910_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10233","volume":"3","author":"T Mori","year":"2019","unstructured":"Mori T, Crandall CJ, Ganz DA (2019) Cost-effectiveness of sequential teriparatide\/alendronate versus alendronate-alone strategies in high-risk osteoporotic women in the US: analyzing the impact of generic\/biosimilar teriparatide. JBMR Plus 3(11):e10233. https:\/\/doi.org\/10.1002\/jbm4.10233","journal-title":"JBMR Plus"},{"issue":"4","key":"1910_CR30","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1910_CR31","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103(8):2949\u20132957. https:\/\/doi.org\/10.1210\/jc.2018-00163","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1910_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/1060028018798034","volume":"53","author":"QA Le","year":"2019","unstructured":"Le QA, Hay JW, Becker R, Wang Y (2019) Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States. Ann Pharmacother 53(2):134\u2013143. https:\/\/doi.org\/10.1177\/1060028018798034","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1910_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA et al (2008) Medication compliance and persistence: terminology and definitions. Value Health. 11(1):44\u201347. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00213.x","journal-title":"Value Health."},{"issue":"1","key":"1910_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12(1):22. https:\/\/doi.org\/10.1007\/s11657-017-0316-5","journal-title":"Arch Osteoporos"},{"issue":"3","key":"1910_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00198-020-05780-8","volume":"32","author":"E S\u00f6reskog","year":"2021","unstructured":"S\u00f6reskog E, Lindberg I, Kanis JA, \u00c5kesson KE, Willems D, Lorentzon M et al (2021) Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int 32(3):585\u2013594. https:\/\/doi.org\/10.1007\/s00198-020-05780-8","journal-title":"Osteoporos Int"},{"issue":"4","key":"1910_CR36","first-page":"324","volume":"60","author":"JP Brown","year":"2014","unstructured":"Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS et al (2014) Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 60(4):324\u2013333","journal-title":"Can Fam Physician"},{"issue":"5","key":"1910_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D (2013) Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 11(5):485\u2013497. https:\/\/doi.org\/10.1007\/s40258-013-0047-8","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"1910_CR38","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95(9):4380\u20134387. https:\/\/doi.org\/10.1210\/jc.2010-0597","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1910_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733. https:\/\/doi.org\/10.1001\/jama.2016.11136","journal-title":"JAMA"},{"key":"1910_CR40","unstructured":"2021 ASP Drug Pricing Files. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2021-asp-drug-pricing-files2021 [cited 2021 Dec 1]."},{"key":"1910_CR41","unstructured":"Thompson Healthcare M. Drugtopics red book 2018 (online version). http:\/\/truvenhealth.com\/Products\/ Micromedex\/Product-Suites\/Clinical-Knowledge\/REDBOOK."},{"issue":"12","key":"1910_CR42","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1359\/jbmr.090523","volume":"24","author":"ML Kilgore","year":"2009","unstructured":"Kilgore ML, Morrisey MA, Becker DJ, Gary LC, Curtis JR, Saag KG et al (2009) Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999\u20132005. J Bone Miner Res 24(12):2050\u20132055. https:\/\/doi.org\/10.1359\/jbmr.090523","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1910_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13696998.2019.1651122","volume":"23","author":"A Stopeck","year":"2020","unstructured":"Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J et al (2020) Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 23(1):37\u201347. https:\/\/doi.org\/10.1080\/13696998.2019.1651122","journal-title":"J Med Econ"},{"key":"1910_CR44","unstructured":"Physician Fee Schedule. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search?Y=0&T=4&HT=0&CT=3&H1=96413&M=5."},{"issue":"4","key":"1910_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989x06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG (2006) Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 26(4):391\u2013400. https:\/\/doi.org\/10.1177\/0272989x06290497","journal-title":"Med Decis Making"},{"issue":"4","key":"1910_CR46","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","volume":"82","author":"M Hiligsmann","year":"2008","unstructured":"Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82(4):288\u2013292. https:\/\/doi.org\/10.1007\/s00223-008-9117-6","journal-title":"Calcif Tissue Int"},{"issue":"78","key":"1910_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20780","volume":"20","author":"S Davis","year":"2016","unstructured":"Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A et al (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 20(78):1\u2013406. https:\/\/doi.org\/10.3310\/hta20780","journal-title":"Health Technol Assess"},{"issue":"6","key":"1910_CR48","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s1262-3636(07)70154-4","volume":"30","author":"WK Redekop","year":"2004","unstructured":"Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJ (2004) Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 30(6):549\u2013556. https:\/\/doi.org\/10.1016\/s1262-3636(07)70154-4","journal-title":"Diabetes Metab"},{"issue":"1","key":"1910_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","volume":"30","author":"A Balasubramanian","year":"2019","unstructured":"Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A et al (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30(1):79\u201392. https:\/\/doi.org\/10.1007\/s00198-018-4732-1","journal-title":"Osteoporos Int"},{"issue":"3","key":"1910_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/jbmr.3194","volume":"33","author":"DM Black","year":"2018","unstructured":"Black DM, Cauley JA, Wagman R, Ensrud K, Fink HA, Hillier TA et al (2018) The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: the study of osteoporotic fractures. J Bone Miner Res 33(3):389\u2013395. https:\/\/doi.org\/10.1002\/jbmr.3194","journal-title":"J Bone Miner Res"},{"key":"1910_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/627631","volume":"2015","author":"S Silverman","year":"2015","unstructured":"Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E (2015) Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective. J Osteoporos 2015:627631. https:\/\/doi.org\/10.1155\/2015\/627631","journal-title":"J Osteoporos"},{"issue":"10","key":"1910_CR52","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00198-021-05927-1","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Tanaka K, Silverman S, McClung M, Gandra SR, Charokopou M et al (2021) Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Osteoporos Int 32(10):2011\u20132021. https:\/\/doi.org\/10.1007\/s00198-021-05927-1","journal-title":"Osteoporos Int"},{"issue":"2","key":"1910_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li N, Cornelissen D, Silverman S, Pinto D, Si L, Kremer I et al (2021) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics 39(2):181\u2013209. https:\/\/doi.org\/10.1007\/s40273-020-00965-9","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1910_CR54","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38(6):922\u2013928. https:\/\/doi.org\/10.1016\/j.bone.2005.10.022","journal-title":"Bone"},{"issue":"20","key":"1910_CR55","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","volume":"165","author":"DH Solomon","year":"2005","unstructured":"Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414\u20132419. https:\/\/doi.org\/10.1001\/archinte.165.20.2414","journal-title":"Arch Intern Med"},{"key":"1910_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40618-022-01820-8","volume":"19","author":"S De Vincentis","year":"2022","unstructured":"De Vincentis S, Domenici D, Ansaloni A, Boselli G, D\u2019Angelo G, Russo A et al (2022) COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine. J Endocrinol Invest 19:1\u201311. https:\/\/doi.org\/10.1007\/s40618-022-01820-8","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"1910_CR57","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s40618-021-01552-1","volume":"44","author":"A Falchetti","year":"2021","unstructured":"Falchetti A, Mohseni M, Tramontana F, Napoli N (2021) Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic? J Endocrinol Invest 44(11):2521\u20132524. https:\/\/doi.org\/10.1007\/s40618-021-01552-1","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"1910_CR58","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s40618-021-01542-3","volume":"44","author":"RR Narla","year":"2021","unstructured":"Narla RR, Adler RA (2021) Osteoporosis care amidst the prolonged pandemic. J Endocrinol Invest 44(7):1353\u20131361. https:\/\/doi.org\/10.1007\/s40618-021-01542-3","journal-title":"J Endocrinol Invest"},{"key":"1910_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-06010-5","author":"S Nayak","year":"2021","unstructured":"Nayak S, Greenspan SL (2021) Cost-effectiveness of 3 versus 6 years of zoledronic acid treatment before bisphosphonate holiday for women with osteoporosis. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-021-06010-5","journal-title":"Osteoporos Int"},{"key":"1910_CR60","unstructured":"Bureau of Labor Statistics Consumer Price Index. http:\/\/www.bls.gov\/cpi\/."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01910-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01910-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01910-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:19:29Z","timestamp":1674260369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01910-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["1910"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01910-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since this economic analysis was based on literature review and modeling techniques, there was no ethical issure involved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This research was conducted through literature review and modeling techniques, and does not contain any studies with human participants or animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research\u00a0involving human participants and\/or animals"}},{"value":"For this study, informed consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}